Clinical Trial Update: Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating toripalimab in combination with platinum-based chemotherapy, with or without an H1 receptor antagonist, as perioperative treat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Toripalimab (Toripalimab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: NSCLC | Phase 2 | Status: NOT_YET_RECRUITING